NCT05009615 (OBHEALTH) is a NA clinical trial of Green coffee extract in Overweight/Obesity, sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición.

Who is sponsoring NCT05009615?

NCT05009615 is sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición.

What drugs are being tested in NCT05009615?

Interventions in NCT05009615: Green coffee extract, Beta glucan, Green coffee + beta-glucan.

What condition does NCT05009615 study?

NCT05009615 studies Overweight/Obesity, Insulin Resistance.

Is NCT05009615 still recruiting?

NCT05009615 is currently completed. Last updated 17 August 2021.

Last reviewed 2021-08-17 · How we verify

NCT05009615: OBHEALTH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Hydroxycinnamates and Beta-glucans as a Dietary Tool Against Obesity (OBHEALTH)

Completed NA Last updated 17 August 2021

What this trial tests

NA trial testing Green coffee extract in Overweight/Obesity in 30 participants. Completed in 14 December 2019.

Timeline

3 December 2018

Primary endpoint
14 December 2019

14 December 2019

Quick facts

Lead sponsor	Instituto de Ciencia y Tecnología de Alimentos y Nutrición
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	30
Start date	3 December 2018
Primary completion	14 December 2019
Estimated completion	14 December 2019
Sites	1 location across Spain

Drugs / interventions tested

Green coffee extract
Beta glucan
Green coffee + beta-glucan

Conditions studied

Overweight/Obesity — all drugs for Overweight/Obesity →
Insulin Resistance — all drugs for Insulin Resistance →

Sponsor

Instituto de Ciencia y Tecnología de Alimentos y Nutrición

Who can join

Adults 18 to 60, any sex, with Overweight/Obesity or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aimed at assessing the effect of a decaffeinated green coffee extract, rich in hydroxycinnamates, oat beta-glucans or the combination of both bioactive compounds on overweight/obese subjects with hyperglycemia.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Appetite and Satiety Effects of the Acute and Regular Consumption of Green Coffee Phenols and Green Coffee Phenol/Oat β-Glucan Nutraceuticals in Subjects with Overweight and Obesity.
Redondo-Puente M, Mateos R, Seguido MA, García-Cordero J, et al · · 2021 · cited 11× · PMID 34828792 · DOI 10.3390/foods10112511
Sustained Consumption of a Decaffeinated Green Coffee Nutraceutical Has Limited Effects on Phenolic Metabolism and Bioavailability in Overweight/Obese Subjects.
Seguido MÁ, Tarradas RM, González-Rámila S, García-Cordero J, et al · · 2022 · cited 8× · PMID 35745175 · DOI 10.3390/nu14122445
Regular Consumption of Green Coffee Phenol, Oat β-Glucan and Green Coffee Phenol/Oat β-Glucan Supplements Does Not Change Body Composition in Subjects with Overweight and Obesity.
García-Cordero J, Sierra-Cinos JL, Seguido MA, González-Rámila S, et al · · 2022 · cited 8× · PMID 35267313 · DOI 10.3390/foods11050679
Dietary Supplements Containing Oat Beta-Glucan and/or Green Coffee (Poly)phenols Showed Limited Effect in Modulating Cardiometabolic Risk Biomarkers in Overweight/Obese Patients without a Lifestyle Intervention.
García-Cordero J, Mateos R, González-Rámila S, Seguido MA, et al · · 2023 · cited 7× · PMID 37432380 · DOI 10.3390/nu15092223

Verify or expand the search:

Other trials of Green coffee extract

Trials testing the same drug.

NCT03520452 — Effect of Chlorogenic Acids on the Human Vasculature · NA · completed

Other recruiting trials for Overweight/Obesity

Currently open trials in the same condition.

NCT07428187 — Snacking Effects on the Brain Response to Foods and Satiety During Dieting · NA · recruiting
NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity · Phase 2 · recruiting
NCT07382908 — Bioequivalence Study of BGM0504 Injection · Phase 1 · recruiting

Other Instituto de Ciencia y Tecnología de Alimentos y Nutrición trials

Trials by the same sponsor.

NCT06723886 — Antidiabetic Effect of Olive Pomace Oil · NA · recruiting
NCT04998695 — Health Effects of Consuming Olive Pomace Oil · NA · completed
NCT04997122 — Health Effects of Consuming Olive Pomace Oil · NA · completed
NCT04321590 — Efficacy of Hydroxycinnamates and Beta-glucans as a Dietary Tool Against obesity_Pilot Study (OBHEALTH_PS) · NA · completed
NCT06729905 — Study of the Effects of Yerba Mate on Cardiometabolic Health · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05009615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto de Ciencia y Tecnología de Alimentos y Nutrición
Last refreshed: 17 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05009615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing